May 17 |
Regeneron wins temporary restraining order preventing Eylea generic launch
|
May 16 |
These 2 No-Brainer Growth Stocks Are Breaking New Ground
|
May 14 |
Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
|
May 14 |
Evercore says biotech ‘winter is finally thawing’
|
May 13 |
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
|
May 13 |
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
|
May 13 |
Pipeline Moves: Phase III completion for Corcept’s relaorilant
|
May 13 |
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
|
May 10 |
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
|
May 10 |
Q1 2024 Intellia Therapeutics Inc Earnings Call
|